James C McMillen1, Christy M Lawson2, A Shaun Rowe3. 1. Department of Pharmacy. 2. Department of Surgery. 3. Department of Clinical Pharmacy, The University of Tennessee Health Science Center, Collage of Pharmacy, Knoxville, Tennessee.
Abstract
OBJECTIVE: Recombinant human factor VII activated (rFVIIa) is an adjuvant therapy in patients receiving massive transfusion for hemorrhagic shock. We compared patient characteristics and outcomes to determine futility criteria for the administration of rFVIIa in patients receiving massive transfusion for hemorrhagic shock. METHODS: This was a retrospective cohort analysis of patients who received both massive transfusion and rFVIIa. Consecutive trauma patients were allocated to 1 of 2 cohorts: survivors and nonsurvivors. RESULTS: Seventy-two subjects comprised the study: 27 were survivors and 45 were nonsurvivors. A univariate analysis revealed that nonsurvivors were older and had a more profound coagulopathy as measured by prothrombin time. A stepwise logistic regression revealed an increased odds of death in those patients who were older (odds ratio [OR], 1.048; 95% CI, 1.008 -1.091), had a higher admission prothrombin time (OR, 1.561; 95% CI, 1.152-2.116), and received more fresh frozen plasma (OR, 1.098; 95% CI 1.023-1.179). In addition we saw a protective effect with increased platelet administration (OR, 0.645; 95% CI, 0.446-0.932). CONCLUSION: The use of rFVIIa for massive transfusion in middle-aged patients with moderate coagulopathy experiencing hemorrhagic shock may be considered futile. However, if rFVIIa is to be used as part of a massive transfusion protocol, adequate administration of platelets should be ensured.
OBJECTIVE: Recombinant humanfactor VII activated (rFVIIa) is an adjuvant therapy in patients receiving massive transfusion for hemorrhagic shock. We compared patient characteristics and outcomes to determine futility criteria for the administration of rFVIIa in patients receiving massive transfusion for hemorrhagic shock. METHODS: This was a retrospective cohort analysis of patients who received both massive transfusion and rFVIIa. Consecutive traumapatients were allocated to 1 of 2 cohorts: survivors and nonsurvivors. RESULTS: Seventy-two subjects comprised the study: 27 were survivors and 45 were nonsurvivors. A univariate analysis revealed that nonsurvivors were older and had a more profound coagulopathy as measured by prothrombin time. A stepwise logistic regression revealed an increased odds of death in those patients who were older (odds ratio [OR], 1.048; 95% CI, 1.008 -1.091), had a higher admission prothrombin time (OR, 1.561; 95% CI, 1.152-2.116), and received more fresh frozen plasma (OR, 1.098; 95% CI 1.023-1.179). In addition we saw a protective effect with increased platelet administration (OR, 0.645; 95% CI, 0.446-0.932). CONCLUSION: The use of rFVIIa for massive transfusion in middle-aged patients with moderate coagulopathy experiencing hemorrhagic shock may be considered futile. However, if rFVIIa is to be used as part of a massive transfusion protocol, adequate administration of platelets should be ensured.
Authors: Philip C Spinella; Jeremy G Perkins; Daniel F McLaughlin; Sarah E Niles; Kurt W Grathwohl; Alec C Beekley; Jose Salinas; Sumeru Mehta; Charles E Wade; John B Holcomb Journal: J Trauma Date: 2008-02
Authors: Kenneth David Boffard; Bruno Riou; Brian Warren; Philip Iau Tsau Choong; Sandro Rizoli; Rolf Rossaint; Mads Axelsen; Yoram Kluger Journal: J Trauma Date: 2005-07
Authors: Carl J Hauser; Kenneth Boffard; Richard Dutton; Gordon R Bernard; Martin A Croce; John B Holcomb; Ari Leppaniemi; Michael Parr; Jean-Louis Vincent; Bartholomew J Tortella; Jeannett Dimsits; Bertil Bouillon Journal: J Trauma Date: 2010-09
Authors: Michael N Diringer; Brett E Skolnick; Stephan A Mayer; Thorsten Steiner; Stephen M Davis; Nikolai C Brun; Joseph P Broderick Journal: Stroke Date: 2008-01-31 Impact factor: 7.914
Authors: Raj K Narayan; Andrew I R Maas; Lawrence F Marshall; Franco Servadei; Brett E Skolnick; Michael N Tillinger Journal: Neurosurgery Date: 2008-04 Impact factor: 4.654